Literature DB >> 21744426

Blood-based biomarkers can differentiate ulcerative colitis from Crohn's disease and noninflammatory diarrhea.

Robert Burakoff1, Samuel Chao, Molly Perencevich, Jay Ying, Sonia Friedman, Frederick Makrauer, Robert Odze, Hema Khurana, Choong-Chin Liew.   

Abstract

BACKGROUND: Blood gene expression profiling has been used in several studies to identify patients with a number of conditions and diseases. A blood test with the ability to differentiate Crohn's disease (CD) from ulcerative colitis (UC) and noninflammatory diarrhea would be useful in the clinical management of these diseases.
METHODS: Affymetrix U133Plus 2.0 GeneChip oligonucleotide arrays were used to generate whole blood gene expression profiles for 21 patients with UC, 24 patients with CD, and 10 control patients with diarrhea, but without colonic pathology.
RESULTS: A supervised learning method (logistic regression) was used to identify specific panels of probe sets which were able to discriminate between UC and CD and from controls. The UC panel consisted of the four genes, CD300A, KPNA4, IL1R2, and ELAVL1; the CD panel comprised the four genes CAP1, BID, NIT2, and NPL. These panels clearly differentiated between CD and UC.
CONCLUSIONS: Gene expression profiles from blood can differentiate patients with CD from those with UC and from noninflammatory diarrheal disorders.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744426     DOI: 10.1002/ibd.21574

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  24 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

2.  Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells.

Authors:  Venkateswara R Simhadri; John F Andersen; Eric Calvo; Seung-Chul Choi; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2012-02-01       Impact factor: 22.113

Review 3.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

Review 4.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

Review 5.  The CD300 molecules: an emerging family of regulators of the immune system.

Authors:  Francisco Borrego
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

Review 6.  New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.

Authors:  Edward L Barnes; Robert Burakoff
Journal:  Inflamm Bowel Dis       Date:  2016-12       Impact factor: 5.325

Review 7.  Potential value of nutrigenomics in Crohn's disease.

Authors:  Lynnette R Ferguson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-03-13       Impact factor: 46.802

8.  Use of blood based biomarkers in the evaluation of Crohn's disease and ulcerative colitis.

Authors:  Edward L Barnes; Choong-Chin Liew; Samuel Chao; Robert Burakoff
Journal:  World J Gastrointest Endosc       Date:  2015-11-25

9.  A key requirement for CD300f in innate immune responses of eosinophils in colitis.

Authors:  I Moshkovits; H Reichman; D Karo-Atar; P Rozenberg; E Zigmond; Y Haberman; N Ben Baruch-Morgenstern; M Lampinen; M Carlson; M Itan; L A Denson; C Varol; A Munitz
Journal:  Mucosal Immunol       Date:  2016-04-27       Impact factor: 7.313

10.  Enhanced efferocytosis by dendritic cells underlies memory T-cell expansion and susceptibility to autoimmune disease in CD300f-deficient mice.

Authors:  L Tian; S-C Choi; H-N Lee; Y Murakami; C-F Qi; M Sengottuvelu; O Voss; K Krzewski; J E Coligan
Journal:  Cell Death Differ       Date:  2016-01-15       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.